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INTRODUCTION
Biocatalysis has evolved from a field of research that observes the natural catalytic properties of enzymes to one that expands the reactivity of existing enzymes and creates entirely new enzymes with reactivity never before seen in nature.
1 This paradigm shift was largely spurred by advances in molecular biology and the development of systematic methods for altering proteins properties through iterative rounds of genetic modification (i.e. directed evolution).
2 Directed evolution efforts have primarily targeted broadening solvent tolerance, increasing temperature stability, expanding substrate scope, and increasing reaction selectivity (enantio-, diastereo-, regio-, and chemoselectivity). 3 The catalysts accessed via directed evolution are superb catalytic species, capable of providing synthetic methods with superior efficiency to those achieved using small molecule catalysts. 4 The chief limitation to further adoption of biocatalytic processes is the breadth of reactions accessible to this catalytic manifold.
Addressing this limited reaction breadth has become the focus of intense interest in the last decade. 5 The pursuit of catalytic promiscuity in biocatalysis has largely centered on finding new reactions that proceed via mechanisms that rely on intermediates that are similar to those of the natural reaction. This is perhaps best epitomized in the hydrolase literature where common hydrolases are shown to be effective catalysts for Aldol, Michael, and Mannich reactions, among many others. 6 After the discovery of new reactivity, the promiscuous -6-function can be further optimized via extensive protein engineering. 7 While effective, this approach is restricted to reactions that share mechanistic similarities with natural reactions. As a consequence, large swaths of non-natural reactions are inaccessible via this method. In particular, the wealth of reactions catalyzed by transition metals are largely inaccessible. An approach to encompass these reactions is to place a transition metal into a protein active site, either in the form of artificial metalloenzymes or natural metalloenzymes and explore their potential to catalyze reactions that the metal cofactor may catalyze
independently.
An early manifestation of this goal was the formation of artificial metalloenzymes, where a catalytically active transition metal is selectively incorporated into a protein scaffold. In the mid-1970's Kaiser and Whitesides demonstrated that such hybrid catalysts could be formed and provide catalytic activity for oxidation and reduction reactions. 8, 9 Since these seminal reports, studies in the field have largely focused on how to selectively introduce different transition metal complexes into a variety of protein scaffolds via dative, covalent, or supermolecular anchoring while maintaining or enhancing the catalytic activity of the metal. 10 A complementary approach is to use proteins that have a natural affinity for a cofactor capable of catalyzing non-natural reactions in the absence of the protein scaffold. Both of these approaches represent only the first-step in developing metalloenzyme catalysts capable of catalyzing non-natural reactions.
In order to create a hybrid that truly benefits from both the protein and transition -7-metal components, the protein component must be genetically engineered for the desired traits. While genetic modification of natural enzymes is applied routinely both in academia and in industry, the same does not hold true for artificial metalloenzymes. 11 Perhaps the greatest challenge towards directed evolution of artificial metalloenzymes is to maintain catalytic efficiency of the cofactor in the presence of unpurified protein samples. 12 Indeed, many organometallic cofactors are inhibited in the presence of cellular extracts (e.g. DNA, proteins, metabolites, lipids etc.). This sets a stringent requirement on the use of purified protein samples for the optimization of artificial metalloenzymes. This prerequisite thus limits the number of samples that can be screened as parallel protein purification is time consuming. This review summarizes the efforts towards the genetic optimization of artificial metalloenzymes for catalytic reactivity and selectivity.
Genetic modifications of protein scaffolds to enable transition metal docking (i.e. bioconjugation) have recently been reviewed and will not be further discussed herein. 10 Our aim is to identify broadly applicable strategies for genetically engineering metalloenzymes. Ultimately, these should be applicable toward other types of metalloenzymes and thus expand the field from one that looks simply to find effective hybrid catalysts to one that aims at exploiting these systems to address challenges that neither small molecules catalysts nor enzymes can currently address. Two complementary strategies are summarized in this review:
i) repurposing natural metalloenzymes towards non-natural reactions (Sections 2 and 6) and ii) introducing an abiotic cofactor within a protein scaffold to generate -8-artificial metalloenzymes (Sections 3-5). Artificial metalloezymes resulting from chemically synthesized host protein/peptides (i.e. solid-phase synthesis) have been recently reviewed and will not be presented herein. 10 The focus of this review is set on the genetic strategies for the optimization of the performance of (artificial) metalloenzymes.
Natural Metalloenzymes that Catalyze Non-Natural Reactions

Cytochrome P450s
Cytochrome P450s are widespread and powerful enzymes that oxidize olefins, heteroatoms, and inert C-H bonds using molecular oxygen or hydrogen peroxide as oxidant. 13 Essential for this reactivity is the iron porphyrin heme cofactor. Aside from effecting oxygenation, iron porphyrins are known to catalyze the cyclopropanation of alkenes with diazoesters. 14 Arnold was interested in exploring the ability of P450s to catalyze carbene transfer reactions. 15 In a seminal report, P450 BM3 was shown to be an effective catalyst for the cyclopropanation of styrenes using ethyl diazoacetate (EDA) as a carbene source under anaerobic conditions, providing product with low conversion and selectivity (5 TTNs). 16 A single mutation of the conserved distal threonine (T268), hypothesized to facilitate proton transfer in the natural reactivity, to alanine (P450 BM3 -T268A) enabled trans-selective cyclopropanation in high yield and enantioselectivity (Figure 1) . The cis-diastereomer was accessed preferentially using a variant that contained 14 mutations from wild-type (P450 BM3 -CIS), in modest yield and diastereoselectivity but with excellent enantioselectivity ( Figure   - -10-T175I, A184V, S226R, H236Q, E252G, T268A, A290V, L353V, I366V, T438S, E442K.
To facilitate reduction, Arnold explored the impact of heme-ligation on the redox potential of the heme-cofactor. 18 Remarkably, mutating the cysteine to the isosteric serine, shifts the redox potential from -430 mV ( (named for the shift in the diagnostic CO Soret band), possesses a redox potential well within the range for the biological reductant NADPH (E 0 ' 1 = -320 mV). Furthermore, the P411 BM3 has poor oxygenase reactivity thus eliminating undesired styrene oxide formation. Finally, the efficiency with which the P411 BM3 effects the desired transformation is roughly four times superior that of the P450 BM3 (Figure 2a ). At high substrate concentrations, the best catalyst (P411 BM3 -CIS-T438S) affected the cis-selective cyclopropanation with over 67,000 TTNs and selectivity that was nearly identical to that achieved by the P450 BM3 -CIS-T438S variant (90:10 dr, 99% ee). Crystallographic data suggests that mutation of the axial cysteine to serine does not have a significant impact on the overall fold of the protein (0.52 Å r.m.s. deviation from P450 BM3 ). Introduction of the key axial serine mutation into other P450 scaffolds yields catalysts that are more effective for cyclopropanation than the parent metalloenzyme.
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-11- The axial mutation was further expanded to include residues that are not isosteric with cysteine. 20, 21 This modest screening effort led to the identification of histidine (i.e. T268A-C400H) as the most efficient artificial metalloenzyme for The P411 scaffold is also effective for nitrene transfer reactions. Arnold found that P411 BM3 -T268A could effect benzylic C-H amination on 1,3,5-triethyl benzenesulfonylazide 7, albeit in modest yield. 23 In contrast to the carbene transfer reactivity, Arnold found that P450 BM3 based catalysts were inefficient for While the early reports of P450-and P411-catalyzed C-H amination used relatively rigid sulfonylazides as substrates; Fasan found that more flexible carbonazidates can be converted to oxazolidinones in modest yield using P450 BM3 -FL#62. 26 A variety of carbonazidates were effective substrates providing between 6 and 100 turnovers albeit with low enantioselectivity. Ease of synthesis opened the ability to explore the mechanism of enzyme catalyzed amination reactions. Mechanistic studies using cis-and trans-homoallyl carbonazidates (14 and 15 respectively) show isomerization to the transoxazolidinone 16 suggesting that the reaction proceeds via C-H abstraction to generate a long-lived allylic or benzylic radical followed by radical recombination (Figure 6 ). Furthermore, kinetic isotope studies suggest C-H abstraction to be rate-limiting. . 27 The architecture of the active site is essential for catalysis in intermolecular nitrene transfer. In unoptimized active sites, the dominant product was the reduction of the azide to the corresponding sulfonamide. It is believed that this reduction occurs via electron transfer from the reductase domain of the P411 to the iron-nitrenoid. In the presence of an optimized active site, sulfimidation became competitive with nitrenoid reduction. Hammett studies revealed a strong correlation between sulfide electronics and rate of sulfimidation, where electron-rich sulfides were amidated faster than electron neutral sulfides.
Sulfimidation served as a gateway to the more challenging alkene aziridination ( Figure 7) . 28 While protein scaffolds identified in the sulfimidation study provided only traces of aziridine, introduction of I263F into the active site provided a substantial amount of aziridine, albeit in modest enantioselectivity.
After two rounds of site-saturation mutagenesis to target residues in the active site, a variant was identified that provides aziridines in excellent enantioselectivity. In contrast to sulfimidation, where the substrate electronics largely dictate the substrate scope, the optimized aziridination catalyst tolerates -17-an array of alkenes where electronics have little effect on the reaction efficiency and selectivity.
Figure 7
Sulfimidation-and aziridination-catalyzed by evolved cytochrome P411 BM3 variants.
Myoglobin Catalyzed Reactions
Myoglobin is a heme protein that serves as an oxygen carrier in mammals with no catalytic function. With respect to heme binding, myoglobin is structurally related to peroxygenases where the iron heme is ligated by a histidine residue.
Despite these similarities, myoglobin is less efficient than peroxidase in effecting oxidations. 29 This is attributed to the lack of a substrate binding cleft and the poorly positioned proximal histidine required to generate compound I. Hayashi hypothesized that the absence of a binding cleft could be overcome by replacing the polar carboxylates of the heme with non-polar aromatic groups. 30 By extracting the cofactor and reconstituting with a "double-winged cofactor", Hayashi achieved superior reactivity for the oxidation of 2-methoxyphenol. This Imidazole-ligated iron-porphyrins are known to be efficient small molecule catalysts for carbene transfer reactions. 31 Fasan found that, in the presence of EDA and various primary and secondary anilines, myglobin is able to effect carbene insertion into N-H bonds with efficiencies that surpass hemin alone ( Figure 9 ). 32 As mentioned above, one drawback of WT myoglobin is its lack of In addition to N-H insertion and cyclopropanation, myoglobin also catalyzes carbene insertion into S-H bonds. 34 In this case however, the best variant for S-H insertion is L29A-H64V. This variant provides activity for a range of substituted aromatic and aliphatic thiols, a feat not possible in the N-H insertion or cyclopropanation chemistry. Furthermore, sterically bulky cyclohexane, tert-butyl, and benzyl substituent diazoesters all provide excellent yields. A brief screen of active site mutants provided a variant (F43V) that is capable of rendering this transformation asymmetric.
Figure 9
Myoglobin-catalyzed carbene insertion into N-H bonds, alkenes, and S-H bonds.
Much like P450s, myoglobin is also able to effect C-H amination via nitrene transfer, albeit in modest yield. 35 Mutation of the conserved distal histidine to valine (H64V) provides a modest increase in catalyst activity. Through modification of the active site, the enantioselectivity of the insertion can be modulated. In general, myoglobin is less effective for reactions involving nitrenoid species than carbenoid species. To address this issue, Fasan explored exchanging the heme cofactor by Mn and Co hemin species that are known to be more effective for amination under organic conditions. Unfortunately, they were less effective that Fe-hemin. In the initial report, acetophenone derivatives were the only substrates to provide high enantioselectivity. Selectivity for dialkyl ketone reduction was addressed using iterative rounds of site saturation mutagenesis (Figure 11 ). butanone. To accelerate the screening process, the streptavidin mutant was extracted from crude cell extracts using biotin-sepharose beads. Importantly, when Sav is present in excess, the sepharose-bound biotin only occupies one biotin-binding site, leaving the other three sites available for catalysis. It was quickly identified that the S112A and S112K variants favored the opposite enantiomers with both arene-capping groups but with modest enantioselectivity.
Supramolecular Docking
Biotin-Streptavidin based Artificial Metalloenzymes
When these mutation were coupled with site saturation libraries at position K121 and L124, substantially improved enantioselectivities were achieved. In order to upgrade the enantiopurity of the amine, the artificial imine reductase may be coupled to an amine oxidase (monoamine oxidase, MAO). 48 In this A challenge for ArMs is to overcome the loss of activity resulting from placing the metal in a protein active site. In the case of the imine reductase, the free metal cofactor is roughly 20x more active than the ArM in a WT-Sav 
■ RESULTS AND DISCUSSION
With the aim of quantifying the effect of streptavidin isoforms (hereafter, Sav) on the catalytic performance of the biotinylated d 6 piano stool complex [Cp*Ir(biot-p-L)Cl], we set out to determine the saturation kinetic behavior for the asymmetric transfer hydrogenation of 1-methyl-3,4-dihydroisoquinoline 1 to the corresponding enantioenriched amine 2 (Scheme 1), striving for a higher catalytic efficiency 14 rather than an improved enantioselectivity. 15, 16 As a starting point, we determined the kinetic profiles for the isolated catalyst precursor [Cp*Ir(biot-p-L)Cl] as well as for the artificial metalloenzyme resulting from its incorporation The concept of protein coordination for increased reactivity was applied to the development of an artificial metalloenzyme for Rh(III)-catalyzed C-H activation of amides to provide dihydroisoquinolones, (Figure 16) . 54 With such catalytic systems, all three available coordination sites of the piano stool moiety are required for the reaction to proceed. Therefore opportunities for exogenous stereocontrol are limited. Ward and Rovis found that, in the presence of WT Sav, a biotinylated {Cp*Rh}-moiety provided enantioenriched product, but in low yield.
Building on the fact that electrophilic C-H activation requires a base, often a carboxylate, to facilitate the C-H activation event, aspartate and glutamate residues were engineered in close proximity to the metal. When aspartic acid was introduced at K121D, the productivity was enhanced. The most active variant, N118K-K121E, provided a nearly 100-fold increase in activity by comparison to WT Sav. When combined with the sterically bulky tyrosine at position S112, a mutant (i.e. S112Y-K121E) was found that could provide high yield and enantioselectivity for the desired product. This represented the first example of a enantioselective Rh(III) C-H activation process and the first example of placing a mechanistically essential residue on the a protein scaffold of an artificial metalloenzyme.
-32- Artificial metalloenzymes are also able to catalyze other reactions that were typically considered to be strictly limited to small molecule catalysis. This is the case in the allylic alkylation of 1,3-diphenylallyl acetate 35 (Figure 17) . 55 It is well known that soft nucleophiles directly attack the η 3 -bound allyl moiety rather than proceeding through metal coordination followed by reductive elimination.
Ward found that combining a biotinylated bis-phosphine ligand with a palladium catalyst, the allylation occurs in high yield in modest selectivity. The mutant S112A provided the alkylated product 37 in excellent enantioselecitivity. A single mutation S112Q afforded the opposite (R)-37 in 31 % ee. Introduction of an enantiopure (R)-proline spacer between the biotin anchor and the palladium complex, combined with the double mutant S112G V47G, lead to an increase in enantioselectivity in favor of the (R)-enantiomer (up to 82% ee (R)). Streptavidin-based artificial metalloenzymes can also be effective catalysts for enantioselective Suzuki reactions that form atropisomers ( Figure   18 ). As a model reaction, 1-iodo naphthalene was coupled to 2-methoxy-1-naphthalene boronic acid. After screen a small library of monodentate biotinylated ligands, it was found that electron-rich di-tert-butyl phosphines provided the best yield. A screen of single mutants at position S112 and K121 revealed modest enantioselectivities for K121E (76% ee R). When this mutation was coupled with mutants at position S112 or N118, a mutant capable of providing quantitative yield and 90% ee was achieved with S112Y-K121E. This hybrid catalyst is effective toward a variety of aryl iodides in excellent yield. Two point mutations improve the enantioselectivity from 58 % to 90 %.
Human Carbonic Anhydrase
Human carbonic anhydrase is responsible for the reversible conversion of CO 2 to bicarbonate. 57 Sulfonamides are known to inhibit this activity through coordination of the sulfonamide's nitrogen to the catalytically active zinc. Ward prepared a family of amino-pyridine and sulfonamide-pyridine ligands covalently linked to p-arylsulfonamides and tested their ability to effect transfer hydrogenation of imines. The best results were observed with the sulfonamidepyridine ligand although mutagenesis of the flanking residues failed to provide increased yields or enantioselectivity (55 TON, 32 % ee, Figure 19 ). The X-ray crystal structure of the artificial imine reductase revealed only a partial occupancy of the pianostool moiety within the funnel-shaped hCAII binding site. The authors speculated that this may be caused by the shallow potential energy surface due to the lack of stabilizing interactions between the pianostool and the host protein.
In collaboration with the Baker group, in silico screening lead to the identification of up to eight mutations (L60V-A65T-N67W-E69Y-Q92F-L140M-L197M-C205S) 
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-35-predicted to improve the cofactor · hCAII interactions. 58 These mutants were expressed and tested for their affinity towards the sulfonamide bearing cofactor.
Gratifyingly, both the affinity, the activity and the selectivity were significantly improved compared the the WT hCA II, providing product in 92% ee (Figure 19 ).
Figure 19
Artificial imine reductase based on the sulfonamide-carbonic anhydrase couple. In silico screening lead to the identification of critical residues, ultimately allowing to significantly improve the affinity, the activity and the enantioselectivity of the iridium-based hybrid.
Covalent Anchoring
LmrR-Based Metalloenzymes
Roelfes and coworkers proposed that the hydrophobic pore of the transcriptional repressor from L. lactis (LmrR) might provide an effective environment for the generation of artificial metalloenzymes. 59 They thus selected LmrR, which in its dimeric form, generates a flat hydrophobic pore to host artificial metal cofactors. By introduction of a cysteine residue into the hydrophobic active site, a Cu(II) phenanthroline moiety was bioconjugated into the hydrophobic pore. Initially, the complex was tested on the copper-catalyzed 
Prolyl Oligopeptidase
Typically, metal cofactors in artificial metalloenzymes reside near the surface of the protein of choice. While this can be effective for selective catalysis, a metal in a more enclosed active-site could provide a more selective catalyst.
Lewis pioneered covalently linking metal cofactors to proteins using strainpromoted azide-alkyne cycloadditions, where L-4-azidophenylalanine was genetically introduced using AMBER codon suppression (Figure 21a ). 62 Lewis found that a Rh(II)-dimer can be introduced into the active site of prolyl . 63 The resulting protein, containing 5 mutations, was able to effect cyclopropanation of styrene with donor-acceptor diazoesters in modest yield and enantioselectivity. When histidine was introduced in the active site at position 328 (H328), presumably to decrease conformational freedom and to block one rhodium center, the enantioselectivity increased to 47% ee with modest yield. Introduction of phenylalanine residues in the activity site (F99-F594 or F99, F97) further optimizes the reaction to 74% yield and 92% ee. It is interesting to note that these mutation also substantially decrease the degree of diazo hydrolysis for 2:1 favoring hydrolysis with the 4-alanine mutations, to ~5:1 favoring cyclopropanation over hydrolysis with the best variant.
-39- (Figure 22) . 65 In the course of these studies, metal binding were used for creating and maintaining the quaternary structure, while others served as catalysts. In the artificial folds generated from zinc and cb562 (a heme containing four helix bundle), when a flanking lysine residues is mutated to alanine, appreciable activity was observed on p-nitrophenylacetate and ampicilline. Mutation of residues proximal to the catalytically active zinc-binding site provided a mutant with superior activity. Metalloproteins that lack any catalytic function can be rendered catalytically active using directed evolution. Starting from a retinoid-X-receptor protein, Szostak and Seelig found that through randomization of the two of the loops found in the zinc-finger domain of the protein can induce RNA-ligase activity. 66 To achieve this feat, an in vitro selection based on mRNA-display was 
Outlook
Recent advances by Arnold and Fasan suggest a bright future for repurposing existing metalloprotein function to catalyze synthetically useful, new-to-nature reactions. These heme-containing enzymes have evolved to function in a cellular environment; the repurposed enzymes can thus be screened either in vivo or in the presence of cell lysates. For directed evolution purposes, this represents a major asset as this significantly speeds up the optimization process. The same holds true for the Zn-containing artificial hydrolases which have been evolved without the need to rigorously purify the protein samples. 64, 65, 66 68 This feature has been beautifully exploited by Lewis to evolve an artificial cyclopropanase ( Figure 21 ). This represents a rare example of a biocompatible precious metal catalyst. 69 Alternatively, the chemical reagents Figure 12 ). 12 Affinity tags or chromatography may be exploited for the parallel purification of host proteins. 42, 44 In our view, the future of artificial metalloenzymes lies primarily in the area of synthetic biology rather than in white biotechnology applications. Indeed, complementing metabolic pathways with the catalytic power of abiotic metal cofactors in vivo, may open fascinating perspectives for the synthesis of biofuels or high-added value products. To realize this however, several challenges remain: i) cofactor uptake in vivo; ii) efficient cofactor bioconjugation and iii) in vivo cascade reactions combining ArMs and natural enzymes.
